Like much of the biopharmaceutical industry, Amgen Inc.'s cancer drug strategy is shifting more and more toward immuno-oncology. But while it may not have a first-round checkpoint inhibitor, it has been a pioneer in at least two modes of immunotherapy. Not being married to a single therapeutic modality – antibody, small molecule, cell therapy, vaccine or otherwise – could turn out to be a long-term strength.
Thousand Oaks, California-based Amgen developed the first oncolytic virus – Imlygic (talimogene laherparepvec or T-VEC) – approved in the US. (Also see "Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines" - Pink Sheet, 27 October, 2015.) It also had the first approved bispecific T-cell engager (BiTE) antibody, Blincyto (blinatumomab). (Also see "Amgen gains early US win for BiTE antibody Blincyto" - Scrip, 4 December, 2014
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?